MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$81,737K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Intangible assets impairment los...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Net loss
Purchases of marketable securiti...
Net accretion of discounts on ma...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Restricted cash
82
-
-
-
Net loss
-142,221
-93,053
-92,931
-110,752
Intangible assets impairment loss
41,824
-
-
-
Stock-based compensation
14,273
12,339
8,107
9,787
Net accretion of discounts on marketable securities
-2,074
-1,961
-1,422
-1,724
Depreciation and amortization
874
871
867
916
Non-cash lease expense
516
575
540
537
Gain on bargain purchase in connection with the acelyrin merger
-
-
0
0
Impairment of long-lived assets
0
444
0
529
Research and development prepaid expenses
1,043
436
-2,047
-2,053
Other prepaid expenses and other assets
716
-780
-3,883
-13,250
Other assets, non-current
-4,937
545
462
3,350
Accounts payable
1,262
1,432
5,550
-10,424
Research and development accrued expenses
-387
1,178
-2,848
-6,102
Other accrued expenses and current liabilities
3,783
-9,716
3,482
-3,983
Deferred revenue
341
2,259
2,125
-667
Operating lease liabilities
-1,073
-1,249
-884
-979
Other liabilities, non-current
-39
-
39
0
Deferred tax liability
1,757
-
0
0
Net cash used in operating activities
-81,500
-87,082
-71,907
-110,909
Maturities of marketable securities
108,604
142,862
142,532
161,149
Purchases of marketable securities
39,674
428,384
47,519
137,113
Purchases of property and equipment
237
164
0
0
Cash, cash equivalents and restricted cash acquired in connection with the acelyrin merger
-
-
0
0
Net cash (used in) provided by investing activities
68,693
-285,686
95,013
24,036
Proceeds from public offering of common stock, net of underwriter discounts, commissions and offering costs
0
323,797
-
-
Proceeds from issuance of common stock upon exercise of stock options
11,058
23,191
489
-
Repurchase of common stock shares issued upon early exercised restricted common stock
-
-
0
0
Proceeds from issuance of common stock under the 2024 employee stock purchase plan
1,570
-
829
0
Net cash provided by financing activities
12,628
346,988
1,318
0
Net decrease in cash, cash equivalents and restricted cash
-179
-25,780
24,424
-86,873
Cash, cash equivalents and restricted cash at beginning of period
65,273
91,053
66,629
170,632
Cash, cash equivalents and restricted cash at end of period
65,094
-
-
-
Right-of-use assets obtained in exchange for operating lease liabilities
1,835
-
-
-
Stock options exercise proceeds receivable
724
-
-
-
Cash and cash equivalents
63,706
-
-
-
Restricted cash, non-current
1,388
-
-
-
Total cash, cash equivalents and restricted cash
65,094
65,273
91,053
66,629
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$108,604K
(-24.72%↓ Y/Y)
Proceeds from issuance of
common stock upon...
$11,058K
Proceeds from issuance of
common stock under the...
$1,570K
(104.96%↑ Y/Y)
Net cash (used in)
provided by investing...
$68,693K
(-59.31%↓ Y/Y)
Net cash provided by
financing activities
$12,628K
(1585.98%↑ Y/Y)
Canceled cashflow
$39,911K
Net decrease in
cash, cash...
-$179K
(98.96%↑ Y/Y)
Canceled cashflow
$81,321K
Intangible assets
impairment loss
$41,824K
Stock-based compensation
$14,273K
(-44.31%↓ Y/Y)
Other assets,
non-current
-$4,937K
(-386.54%↓ Y/Y)
Other accrued
expenses and current...
$3,783K
(-42.13%↓ Y/Y)
Accounts payable
$1,262K
(208.61%↑ Y/Y)
Depreciation and
amortization
$874K
(-48.98%↓ Y/Y)
Non-cash lease expense
$516K
(-17.31%↓ Y/Y)
Deferred revenue
$341K
(-86.94%↓ Y/Y)
Purchases of marketable
securities
$39,674K
(61.70%↑ Y/Y)
Purchases of property and
equipment
$237K
(-63.71%↓ Y/Y)
Net cash used in
operating activities
-$81,500K
(56.35%↑ Y/Y)
Canceled cashflow
$67,810K
Net loss
-$142,221K
(-258.76%↓ Y/Y)
Net accretion of
discounts on marketable...
-$2,074K
(3.62%↑ Y/Y)
Deferred tax liability
$1,757K
(-79.48%↓ Y/Y)
Operating lease
liabilities
-$1,073K
(20.46%↑ Y/Y)
Research and development
prepaid expenses
$1,043K
(114.15%↑ Y/Y)
Other prepaid
expenses and other assets
$716K
(845.83%↑ Y/Y)
Research and development
accrued expenses
-$387K
(-103.51%↓ Y/Y)
Other liabilities,
non-current
-$39K
(-123.21%↓ Y/Y)
Buy us a coffee
ALUMIS INC. (ALMS)
ALUMIS INC. (ALMS)